Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.humimm.2021.07.003 http://scihub22266oqcxt.onion/10.1016/j.humimm.2021.07.003 34303556!8266522!34303556     free     free     free       Hum+Immunol 2021 ; 82 (10): 713-718 Nephropedia Template TP {{tp|p=34303556|t=2021. HLA B53 is associated with a poor outcome in black COVID-19 patients |pdf=|usr=}}{{34303556}} gab.com Text HLA B53 is associated with a poor outcome in black COVID-19 patients JO: Hum Immunol http://www.kidney.de/pget.php?&tw=1&pmid=34303556 #FOAvip A disproportionate incidence of death has occurred in African Americans (Blacks) in the United States due to COVID-19. The reason for this disparity is likely to be multi-factorial and may involve genetic predisposition. The association of human leukocyte antigens (HLA) with severe COVID-19 was examined in a hospitalized population (89% Black, n = 36) and compared to HLA typed non-hospitalized individuals (20% Black, n = 40) who had recovered from mild disease. For additional comparison, HLA typing data was available from kidney transplant recipients and deceased donors. Hospitalized patients were followed for 45 days after admission to our medical center with death as the primary end-point. One HLA allele, B53, appeared to be more prevalent in the hospitalized COVID-19 patients (percent of positive subjects, 30.5) compared to national data in US Black populations (percent of positive subjects, 24.5). The percent B53 positive in non-hospitalized COVID-19 patients was 2.6, significantly less than the percent positive in the hospitalized COVID-19 patients (p = 0.001, Fisher's exact test) and less than the 8 percent positive listed in national data bases for US Caucasian populations. Significantly greater deaths (73 percent) were observed in HLA B53 positive hospitalized COVID-19 patients compared to hospitalized COVID-19 patients who were B53 negative (40 percent). Multi-variate analysis indicated that HLA B53 positive Black hospitalized COVID-19 patients were at a 7.4 fold greater risk of death than Black COVID-19 patients who were B53 negative. Consideration for accelerated vaccination and treatment should be given to HLA B53 positive Black COVID19 patients. Twit Text FOAVip HLA B53 is associated with a poor outcome in black COVID-19 patients ????Hum Immunol http://www.kidney.de/pget.php?&tw=1&pmid=34303556 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34303556 #FOAvip English Wikipedia <ref>{{Cite pmid|34303556}}</ref> HLA B53 is associated with a poor outcome in black COVID-19 patients #MMPMID34303556 Norin AJ; Mendoza R; Augenbraun M; Das B Hum Immunol 2021[Oct]; 82 (10): 713-718 PMID34303556show ga A disproportionate incidence of death has occurred in African Americans (Blacks) in the United States due to COVID-19. The reason for this disparity is likely to be multi-factorial and may involve genetic predisposition. The association of human leukocyte antigens (HLA) with severe COVID-19 was examined in a hospitalized population (89% Black, n = 36) and compared to HLA typed non-hospitalized individuals (20% Black, n = 40) who had recovered from mild disease. For additional comparison, HLA typing data was available from kidney transplant recipients and deceased donors. Hospitalized patients were followed for 45 days after admission to our medical center with death as the primary end-point. One HLA allele, B53, appeared to be more prevalent in the hospitalized COVID-19 patients (percent of positive subjects, 30.5) compared to national data in US Black populations (percent of positive subjects, 24.5). The percent B53 positive in non-hospitalized COVID-19 patients was 2.6, significantly less than the percent positive in the hospitalized COVID-19 patients (p = 0.001, Fisher's exact test) and less than the 8 percent positive listed in national data bases for US Caucasian populations. Significantly greater deaths (73 percent) were observed in HLA B53 positive hospitalized COVID-19 patients compared to hospitalized COVID-19 patients who were B53 negative (40 percent). Multi-variate analysis indicated that HLA B53 positive Black hospitalized COVID-19 patients were at a 7.4 fold greater risk of death than Black COVID-19 patients who were B53 negative. Consideration for accelerated vaccination and treatment should be given to HLA B53 positive Black COVID19 patients. |Black or African American/genetics[MESH] |COVID-19/*genetics[MESH] |Female[MESH] |Genetic Predisposition to Disease/*genetics[MESH] |HLA Antigens/*genetics[MESH] |Hospitalization[MESH] |Humans[MESH] |Male[MESH] |SARS-CoV-2/pathogenicity[MESH]HLA B53 is associated with a poor outcome in black COVID-19 patients (epmc).pdf DeepDyve Pubget Overpricing